Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 923,806
  • Shares Outstanding, K 34,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,970 K
  • 60-Month Beta 2.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 35.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.39
  • Low Estimate -0.43
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -32.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.62 +18.66%
on 08/15/19
27.59 -2.72%
on 08/14/19
-0.80 (-2.89%)
since 08/13/19
3-Month
21.86 +22.78%
on 06/17/19
28.70 -6.47%
on 07/29/19
+3.89 (+16.95%)
since 06/13/19
52-Week
1.94 +1,283.51%
on 12/27/18
28.70 -6.47%
on 07/29/19
+23.74 (+765.81%)
since 09/13/18

Most Recent Stories

More News
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society

Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine

AXSM : 26.84 (+4.72%)
Innovative Drug-Delivery Systems Benefit Patients and Businesses

Drugs play an essential role in treating anything from a mild headache to life-threatening disease -- and everything in between. While effectiveness of drugs is what most often captures the spotlight,...

LXRP : 0.6800 (-0.01%)
EXEL : 19.24 (-0.10%)
SGEN : 70.63 (-0.35%)
PRVB : 10.13 (+0.20%)
LXX.CN : 0.870 (-5.43%)
AXSM : 26.84 (+4.72%)
Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in the Morgan...

MS : 45.16 (+1.90%)
AXSM : 26.84 (+4.72%)
Is the Options Market Predicting a Spike in Axsome (AXSM) Stock?

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

AXSM : 26.84 (+4.72%)
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment...

AMGN : 195.47 (+0.76%)
AXSM : 26.84 (+4.72%)
Axsome: 2Q Earnings Snapshot

NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Thursday reported a loss of $13.8 million in its second quarter.

AXSM : 26.84 (+4.72%)
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019

AXSM : 26.84 (+4.72%)
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019

Axsome to host conference call and webcast on Thursday, August 8, 2019 at 8:00 AM Eastern Time

AXSM : 26.84 (+4.72%)
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility

Extends interest-only period and time to access additional funding

AXSM : 26.84 (+4.72%)
Pain Relief Therapeutics Market 2019 Industry Analysis and Opportunities by Top Key Players are Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions Inc., Purdue Pharma L.P.

: The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ORXOY : 5.6300 (+0.09%)
BAYRY : 18.8100 (-0.05%)
BDSI : 4.81 (+1.48%)
MRK : 82.61 (-0.84%)
EGLT : 0.0315 (-63.37%)
NVS : 86.99 (-2.79%)
PFE : 36.91 (-0.99%)
AXSM : 26.84 (+4.72%)
MESO : 7.23 (+7.11%)
BDRFF : 120.6050 (+0.13%)
ABT : 84.27 (-1.10%)
LLY : 110.89 (-0.52%)
ACOR : 3.86 (+0.26%)
FLXN : 13.99 (-0.99%)
DEPO : 7.30 (+1.67%)
NKTR : 20.11 (+0.85%)
VRX.TO : 30.80 (-3.33%)
BMY : 49.43 (-0.36%)
HRTX : 20.51 (unch)
SRNE : 2.32 (unch)
COLL : 11.94 (-1.32%)
DRRX : 1.75 (+2.94%)
ACRX : 2.55 (+4.51%)
KMPH : 0.88 (-1.11%)
REGN : 281.62 (-0.90%)
GLPG : 161.16 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade AXSM with:

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

2nd Resistance Point 28.38
1st Resistance Point 27.61
Last Price 26.84
1st Support Level 25.69
2nd Support Level 24.54

See More

52-Week High 28.70
Last Price 26.84
Fibonacci 61.8% 18.47
Fibonacci 50% 15.32
Fibonacci 38.2% 12.16
52-Week Low 1.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar